Now showing items 1-5 of 5
Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function.
(J Am Soc Nephrol, 2017-10)
Efficacy of statin-based therapies in reducing cardiovascular mortality in individuals with CKD seems to diminish as eGFR declines. The strongest evidence supporting the cardiovascular benefit of statins in individuals with ...
Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.
(J Cardiovasc Pharmacol, 2015-05)
Furosemide has historically been the primary loop diuretic in heart failure patients despite data suggesting potential advantages with torsemide. We used the Duke Echocardiography Lab Database to investigate patients admitted ...
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.
(European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2018-01)
OBJECTIVES:Critical limb ischaemia (CLI) implies an increased risk of cardiovascular morbidity and mortality, and the optimal antithrombotic treatment is not established. DESIGN, MATERIALS, METHODS:The EUCLID trial investigated ...
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
(Vascular medicine (London, England), 2018-12)
Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular morbidity and mortality. We sought to evaluate the risk of concomitant coronary artery disease (CAD) in patients with symptomatic PAD ...
Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial.
(Journal of the American College of Cardiology, 2018-12)
BACKGROUND:Diabetes confers an increased risk for atherosclerotic cardiovascular disease, but less is known about the independent risk diabetes confers on major cardiovascular and limb events in patients with symptomatic ...